23293546|t|Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection.
23293546|a|Olanzapine long acting injection has joined risperidone and paliperidone as the second generation long acting antipsychotic injection options for treatment of patients with schizophrenia. Long acting injections are important alternatives to oral medications for patients who have difficulty adhering to daily or multiple daily medication administrations, yet may be underutilized or not well understood. Patient perceptions, adherence, and preferences are important issues for health care providers to address when discussing treatment options with their patients. Reviewed here are overall patient and health care provider attitudes and perceptions regarding long acting injections and the details of olanzapine long acting injectable, the newest agent, and how it will fit in the marketplace. In addition, efficacy, safety, dosing and use data regarding this newest long acting agent are reviewed and compared to other available long acting agents.
23293546	0	7	Patient	Species	9606
23293546	90	103	Schizophrenia	Disease	MESH:D012559
23293546	128	138	Olanzapine	Chemical	MESH:D000077152
23293546	162	172	Olanzapine	Chemical	MESH:D000077152
23293546	206	217	risperidone	Chemical	MESH:D018967
23293546	222	234	paliperidone	Chemical	MESH:D000068882
23293546	321	329	patients	Species	9606
23293546	335	348	schizophrenia	Disease	MESH:D012559
23293546	424	432	patients	Species	9606
23293546	566	573	Patient	Species	9606
23293546	717	725	patients	Species	9606
23293546	753	760	patient	Species	9606
23293546	864	874	olanzapine	Chemical	MESH:D000077152
23293546	Negative_Correlation	MESH:D000077152	MESH:D012559
23293546	Negative_Correlation	MESH:D018967	MESH:D012559
23293546	Negative_Correlation	MESH:D000068882	MESH:D012559

